FDA Accepts New Drug Application For Teva’s SD-809 To Address Huntington Disease
Teva Pharmaceutical Industries Ltd. has recently announced that its New Drug Application (NDA) for SD-809 (deutetrabenazine) was accepted by the United States Food and Drug Administration (FDA) to treat chorea linked with Huntington’s disease (HD). HD is a fatal and very rare neurodegenerative disorder that results in the progressive damage of brain’s nerve cells; in western countries, it…